Difference between revisions of "Profiles"
Jump to navigation
Jump to search
m |
|||
| Line 6: | Line 6: | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Consensus Profiles=== | ||
| + | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] (''Public Comment ended Feb 2017'') | ||
| + | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]] | ||
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | ||
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | :* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | ||
| Line 18: | Line 20: | ||
'''''Stage 1: Public Comment closed''''' | '''''Stage 1: Public Comment closed''''' | ||
| − | |||
| − | |||
| − | |||
*[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016]] (''Public Comment ended Sept 2016'') | *[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016]] (''Public Comment ended Sept 2016'') | ||
Revision as of 14:48, 26 June 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
- Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 (Public Comment ended Feb 2017)
Stage 1: Public Comment Profiles
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2
- QIBA fMRI Profile 2017-06-19 Public Comment to open on June 19, 2017
- QIBA PET Amyloid Profile 2017-06-15 Public Comment is open until September 15, 2017
- DWI Profile 2017-04-27 Public Comment is open until July 28, 2017
Stage 1: Public Comment closed
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 (Public Comment ended Sept 2016)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)